Uncertainty over future role of NICE in UK
This article was originally published in SRA
Doctors will decide whether or not to make drugs available on the National Health Service to patients in England and Wales and the National Institute for Health and Clinical Excellence will take on more of an advisory role when the new value-based drug pricing system is up and running, says the Department of Health1.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.